TY - JOUR
AU - B. Yetkin-Arik
AU - S. A. Jansen
AU - S. Varderidou-Minasian
AU - B. Westendorp
AU - K.-P. Skarp
AU - M. Altelaar
AU - C. A. Lindemans
AU - M. J. Lorenowicz
AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for leukemia and a range of non-malignant disorders. The success of the therapy is hampered by occurrence of acute graft-versus-host disease (aGvHD); an inflammatory response damaging recipient organs, with gut, liver, and skin being the most susceptible. Intestinal GvHD injury is often a life-threatening complication in patients unresponsive to steroid treatment. Allogeneic mesenchymal stromal/stem cell (MSC) infusions are a promising potential treatment for steroid-resistant aGvHD. Data from our institution and others demonstrate rescue of approximately 40–50% of aGvHD patients with MSCs in Phase I, II studies and minor side effects. Although promising, better understanding of MSC mode of action and patient response to MSC-based therapy is essential to improve this lifesaving treatment.
BT - Stem Cell Research & Therapy
DA - 2024-04-29
DO - 10.1186/s13287-024-03738-9
IS - 1
LA - en
N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for leukemia and a range of non-malignant disorders. The success of the therapy is hampered by occurrence of acute graft-versus-host disease (aGvHD); an inflammatory response damaging recipient organs, with gut, liver, and skin being the most susceptible. Intestinal GvHD injury is often a life-threatening complication in patients unresponsive to steroid treatment. Allogeneic mesenchymal stromal/stem cell (MSC) infusions are a promising potential treatment for steroid-resistant aGvHD. Data from our institution and others demonstrate rescue of approximately 40–50% of aGvHD patients with MSCs in Phase I, II studies and minor side effects. Although promising, better understanding of MSC mode of action and patient response to MSC-based therapy is essential to improve this lifesaving treatment.
PY - 2024
EP - 125
T2 - Stem Cell Research & Therapy
TI - Mesenchymal stromal/stem cells promote intestinal epithelium regeneration after chemotherapy-induced damage
UR - https://doi.org/10.1186/s13287-024-03738-9
VL - 15
Y2 - 2026-01-09
SN - 1757-6512
ER -